Images List Premium Download Classic

Atherosclerosis

Atherosclerosis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3
Regeneron Pharmaceuticals, Inc.
August 17, 2017 - N°20170233466

The present invention provides methods and compositions for treating or preventing atherosclerosis in a subject. The methods of the present invention comprise administering an inhibitor of angiopoietin-like protein-3 (angptl3) to a subject who has atherosclerosis or is at risk of developing atherosclerosis. In certain embodiments, the angptl3 inhibitor is an antibody or antigen-binding fragment thereof that specifically binds angptl3.
Cyclic polypeptides for the treatment of heart failure
Regeneron Pharmaceuticals, Inc.
August 17, 2017 - N°20170233443

Or an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein x1, x3, x4, x7, x8, x9, x10, x11, x12 and x13 are defined herein. The polypeptides are agonist of the apj receptor. The invention also relates to a method for manufacturing the polypeptides of the invention or bioconjugates thereof, and their therapeutic uses such as treatment ...
Organic compounds
Intra-cellular Therapies, Inc.
August 17, 2017 - N°20170233399

The invention relates to novel inhibitors of phosphodiesterase 1 (pde1), useful for the treatment of diseases or disorders characterized by disruption of or damage to certain cgmp/pkg mediated pathways (e. G., in cardiac tissue). The invention further relates to pharmaceutical composition comprising the same and methods of treatment of cardiovascular disease and related disorders, e. G., congestive heart disease, atherosclerosis, ...
Atherosclerosis Patent Pack
Download + patent application PDFs
Atherosclerosis Patent Applications
Download + Atherosclerosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Atherosclerosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Piperazine derivatives as liver x receptor modulators
Vitae Pharmaceuticals, Inc.
August 10, 2017 - N°20170226067

Provided are novel compounds of formula (i): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver x receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver x receptor. Also provided are the compounds of formula (i) and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, alzheimer's disease, dermatitis, dyslipidemia, cancer ...
Methods for reducing ldl-cholesterol
Rinat Neuroscience Corp.
August 10, 2017 - N°20170224816

The present invention relates to methods for the treatment of reducing ldl-cholesterol levels in a subject infected with hepatitis c virus (hcv) or at high risk of contracting hcv comprising administration to the subject in need thereof a therapeutically effective amount of an antagonist antibody which specifically binds to a human pcsk9 protein. The subject treatment can be used in ...
Methods for treating thrombosis using chimeric and humanized anti-histone antibodies
Immunomedics, Inc.
August 03, 2017 - N°20170218059

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the ng1m1,2 or km3 allotypes. The antibodies ...
Atherosclerosis Patent Pack
Download + patent application PDFs
Atherosclerosis Patent Applications
Download + Atherosclerosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Atherosclerosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Sphinogosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders
The Scripps Research Institute
August 03, 2017 - N°20170217963

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, ...
N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and n-(4- hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and ...
Pimco 2664 Limited
August 03, 2017 - N°20170217881

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted n-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as hmc compounds) that are useful, for example, in the treatment of disorders (e. G., diseases) including, inflammation and/or joint destruction ...
Selective removal of age-modified cells for treatment of atherosclerosis
Siwa Corporation
August 03, 2017 - N°20170216435

A method of treating atherosclerosis comprises removing age-modified cells from a patient. The age-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. A variety of techniques, such as ultrasound and binding with an anti-age antibody, may be used to identify and remove the age-modified cells.
Aldose reductase inhibitors and uses thereof
The Trustees Of Columbia University In The City Of New York
August 03, 2017 - N°20170216292

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment ...
Aldose reductase inhibitors and uses thereof
The Trustees Of Columbia University In The City Of New York
August 03, 2017 - N°20170216291

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment ...
Monounsaturated fatty acid compositions and use for treating atherosclerosis
Burke & Boyer Nyc
August 03, 2017 - N°20170216237

Compositions comprising high concentration of monounsaturated fatty acids having low melting points and high iodine values and use of such compositions as dietary supplements, nutraceuticals or pharmaceuticals for reducing atherosclerotic plaque in mammals. It has been found that high concentrations of monounsaturated fatty acids (mufas) having low melting point temperatures and iodine values of about 50 to about 130 can be used ...
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
Merck Sharp & Dohme Corp.
July 27, 2017 - N°20170210715

Compounds having the structure of formula i, including pharmaceutically acceptable salts of the compounds, wherein d1, d2 and d3 are each n, ch, or substituted ch, are cetp inhibitors and are useful for raising hdl-cholesterol, reducing ldl-cholesterol, and for treating or preventing atherosclerosis.
Atherosclerosis Patent Pack
Download + patent application PDFs
Atherosclerosis Patent Applications
Download + Atherosclerosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Atherosclerosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
The John Hopkins University
July 27, 2017 - N°20170209435

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases ...
Compounds
Glaxosmithkline Intellectual Property Development Limited
July 20, 2017 - N°20170204108

The present invention relates to novel compounds that inhibit lp-pla2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of lp-pla2, for example atherosclerosis, alzheimer's disease.
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
The John Hopkins University
July 13, 2017 - N°20170198253

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases ...
Reconstituted high density lipoprotein formulation and production method thereof
Csl Limited
July 13, 2017 - N°20170196935

A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as apoai or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/l and the molar ratio of apolipoprotein:...
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
The John Hopkins University
July 13, 2017 - N°20170196858

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases ...
Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
The John Hopkins University
July 13, 2017 - N°20170196857

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases ...
Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease
Thymon, Llc
July 06, 2017 - N°20170190768

An isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human tnf. Such binding disrupts assembly of the monomer into bioactive trimeric human stnf. A pharmaceutical composition contains one or more antibodies or ligands: (a) an antibody or ligand that specifically binds the tnf monomer-specific epitope having the sequence psdkpvah ...
Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
Pharsogen
June 29, 2017 - N°20170183416

Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (pah), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
Loading